ScholarIQanswers from OpenAlex & ORCID
Melinda Gooderham
ResearcherPublications, citations & collaboration network
Melinda Gooderham is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Melinda Gooderham have?
ScholarIQindexed works
Melinda Gooderham has 579 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Melinda Gooderham have?
ScholarIQcitation count
Melinda Gooderham has 16,115 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Melinda Gooderham?
ScholarIQh-index
Melinda Gooderham has an h-index of 60 in OpenAlex.
What is the i10-index of Melinda Gooderham?
ScholarIQi10-index
Melinda Gooderham has an i10-index of 199 in OpenAlex.
What is the ORCID of Melinda Gooderham?
ScholarIQorcid
The ORCID for Melinda Gooderham is on the source record.
What is the OpenAlex record for Melinda Gooderham?
ScholarIQopenalex
The OpenAlex for Melinda Gooderham is on the source record.
What are the most-cited papers on Melinda Gooderham?
ScholarIQmost cited works
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham, Jennifer Clay Cather, Jamie Weisman, David M. Pariser, Eric L. Simpson, Kim Papp, Hyuck-Ki Hong, Diana Rubel, Peter Foley, Errol P. Prens, C.E.M. Griffiths, Takafumi Etoh, Pedro Herranz, Ramón M. Pujol, Jacek C. Szepietowski, Karel Ettler, Lajos Kemény, Xiaoping Zhu, Bolanle Akinlade, Thomas Hultsch, Vera Mastey, Abhijit Gadkari, Laurent Eckert, Nikhil Amin, Neil M.H. Graham, Gianluca Pirozzi, Neil Stahl, George D. Yancopoulos, Brad Shumel
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G. Krueger, J.‐P. Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen K. Tyring, B Berner, Sudha Visvanathan, Chandrasena Pamulapati, Nathan Bennett, Mary Flack, Paul Scholl, Steven J. Padula
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
Eric L. Simpson, Amy S. Paller, Elaine C. Siegfried, Mark Boguniewicz, Lawrence Sher, Melinda Gooderham, Lisa A. Beck, Emma Guttman‐Yassky, David M. Pariser, Andrew Blauvelt, Jamie Weisman, Benjamin Lockshin, Thomas Hultsch, Qin Zhang, Mohamed Kamal, John D. Davis, Bolanle Akinlade, Heribert Staudinger, Jennifer D. Hamilton, Neil M.H. Graham, Gianluca Pirozzi, Abhijit Gadkari, Laurent Eckert, Neil Stahl, George D. Yancopoulos, Marcella Ruddy, Ashish Bansal
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
C. Paul, Jennifer Clay Cather, Melinda Gooderham, Yves Poulin, Ulrich Mrowietz, C. Ferrandiz, J. Crowley, ChiaChi Hu, R.M. Stevens, Kara N. Shah, R. M. Day, Giampiero Girolomoni, A.B. Gottlieb
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
Kim Papp, Kenneth B. Gordon, Diamant Thaçi, Akimichi Morita, Melinda Gooderham, Peter Foley, Ihab Girgis, Sudeep Kundu, Subhashis Banerjee